For research and educational purposes only. Not medical advice.

Lixisenatide Reference

Educational, not medical advice reference for Lixisenatide: GLP-1, Fat Loss, Metabolic; regulatory status, evidence posture, source review, and…

Reference summary

Lixisenatide was the only short-acting prandial GLP-1 RA on the US market until Sanofi withdrew it commercially in 2023. pepSmart surfaces label-reference content only.

Regulatory and posture

Categories
GLP-1, Fat Loss, Metabolic
Aliases
Adlyxin, AVE0010, Lyxumia (EU), Prandial GLP-1 RA
Evidence posture
human - FDA-approved but commercially discontinued in the US since early 2023 (business decision, not safety / efficacy). Acute pancreatitis is a label-level warning. Hypoglycemia risk increases when combined with insulin or sulfonylureas.
Regulatory status
FDA-approved prescription medication (Adlyxin). Initial US approval 2016. Indicated as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes. Not approved as a weight-loss drug. Sanofi discontinued US sales in early 2023 for business reasons; the FDA approval remains on file but Adlyxin is no longer commercially available in the US.
Content review status
label verified

Selected public sources

Related tools